Mainz Biomed N.V. announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), the development bank of the German federal state of Rheinland-Pfalz. The state will fund up to 50% of the project’s total costs.
This direct governmental support represents a strong endorsement of the scientific and societal value of Mainz Biomed’s non-invasive, blood-based screening test for the early detection of pancreatic cancer. The funding is expected to accelerate the development of this critical diagnostic solution.
The project is currently in its feasibility phase, where Mainz Biomed, in collaboration with Crown Bioscience, is evaluating the performance of a panel of mRNA biomarkers and a machine learning-driven algorithm using real clinical blood samples. This funding will help close a critical gap in cancer diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.